siRNA Sequences

siRNA Sequences

ExoPTEN uses a proprietary small inhibiting RNA sequence to inhibit PTEN expression. Among suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.

Intranasal administration of ExoPTEN led to significant motor improvement, sensory recovery, and faster urinary reflex restoration. Functional recovery was accompanied by biological changes of reduced neuroinflammation and gliosis, increased axonal regeneration and angiogenesis, and structural and electrophysiological improvements.

In addition, the Company has developed two new selective siRNA sequences that target and inhibit proteins within the Peri-Neural Network (PNN) complex (Fig. A). The breakthrough sequences, detailed in a patent application held by NurExone, are built upon a scientifically validated strategy for enhanced neuronal regeneration via inhibition of the PNN complex. 

The Company believes that its innovative approach, using the Company’s ExoTherapy platform to deliver these RNA sequences, may overcome limitations of previous methods. The promise of the Company’s new sequences is evident in Figures B-C, where PNN is notably reduced post-treatment.

(A) Illustration of the extracellular Perineural network (PNN), highlighted in green.

(B) Immunohistology of one protein in the PNN in differentiated neuronal culture demonstrates the new treatment on human neuronal culture successfully degraded the PNN.

(C) Quantification of one PNN building block protein that was successfully inhibited by the new treatment.

Set layout popup